How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
CoolSculpting or Zeltiq Market
- By Treatment Area: Abdomen, Flanks (Love Handles), Thighs, Double Chin (Submental Area), Upper Arms, Back (Bra Fat)
- By End User: Medical Spas, Dermatology Clinics, Plastic Surgery Clinics, General Hospitals, Aesthetic Clinics
- By Technology Type: Cryolipolysis Devices, Vacuum Suction Applicators, Cooling Panels, Handheld Applicators
- By Application: Body Contouring, Fat Reduction, Cellulite Reduction, Skin Tightening
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Abdomen leads By Treatment Area at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.167 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.175 →
Full report · locked preview
Everything inside the CoolSculpting or Zeltiq Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Treatment Area 6
End User 5
Technology Type 4
Application 4
Companies profiled
Allergan (AbbVie)
Zeltiq Aesthetics (acquired by Allergan)
Cynosure (a division of Hologic)
Cutera Inc.
Lumenis Ltd.
Syneron Candela
BTL Industries
Venus Concept
InMode Ltd.
Alma Lasers (part of Sisram Medical)
Sciton Inc.
Hugel Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Allergan (AbbVie)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Zeltiq Aesthetics (acquired by Allergan)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Cynosure (a division of Hologic)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Cutera Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Lumenis Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Syneron Candela
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →BTL Industries
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Venus Concept
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →InMode Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Alma Lasers (part of Sisram Medical)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sciton Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Hugel Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Jeisys Medical Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Fotona
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Mediostar
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,271M by 2033 · 6.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Abdomen35.9
- Flanks (Love Handles)8.0
- Thighs7.8
- Double Chin (Submental Area)15.9
- Upper Arms14.6
- Back (Bra Fat)17.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$880.8M → $1,536M · 7.2%
Europe$613.9M → $1,028M · 6.7%
Asia Pacific$560.5M → $845.9M · 5.3%
Latin America$347.0M → $552.4M · 6.0%
Middle East and Africa$266.9M → $414.9M · 5.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.012026
6.022027
6.022028
6.052029
6.052030
6.062031
6.092032
6.092033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Allergan (AbbVie)20.7
- Zeltiq Aesthetics (acquired by Allergan)16.7
- Cynosure (a division of Hologic)10.8
- Cutera Inc.10.0
- Lumenis Ltd.8.4
- Syneron Candela5.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Area24.0%
End User15.7%
Technology Type42.4%
Application18.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.1
- Europe23.5
- Asia Pacific19.3
- Latin America12.6
- Middle East and Africa9.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Allergan (AbbVie) | 85 | 81 | 91 | 87 | 76 | 94 | 86 |
| Zeltiq Aesthetics (acquired by Allergan) | 80 | 75 | 68 | 79 | 79 | 92 | 79 |
| Cynosure (a division of Hologic) | 65 | 78 | 74 | 81 | 86 | 87 | 79 |
| Cutera Inc. | 59 | 72 | 62 | 74 | 64 | 64 | 66 |
| Lumenis Ltd. | 73 | 73 | 68 | 73 | 64 | 54 | 68 |
| Syneron Candela | 50 | 65 | 61 | 63 | 48 | 69 | 59 |
| BTL Industries | 51 | 46 | 62 | 45 | 62 | 55 | 54 |
| Venus Concept | 45 | 58 | 50 | 43 | 39 | 45 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Allergan (AbbVie)
- Zeltiq Aesthetics (acquired by Allergan)
- Cynosure (a division of Hologic)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Allergan (AbbVie) | ✓ | ◐ | ✓ | ✓ | ◐ | ◐ |
| Zeltiq Aesthetics (acquired by Allergan) | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Cynosure (a division of Hologic) | − | ✓ | ◐ | ✓ | ✓ | ✓ |
| Cutera Inc. | − | − | ◐ | ✓ | ◐ | ◐ |
| Lumenis Ltd. | ◐ | ✓ | − | ✓ | ◐ | − |
| Syneron Candela | − | − | ◐ | − | ◐ | ◐ |
| BTL Industries | − | − | − | ◐ | − | ◐ |
| Venus Concept | − | ◐ | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Allergan (AbbVie)86
2Zeltiq Aesthetics (acquired by Allergan)79
3Cynosure (a division of Hologic)79
4Lumenis Ltd.68
5Cutera Inc.66
6Syneron Candela59
7BTL Industries54
8Venus Concept47
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Allergan (AbbVie)Zeltiq Aesthetics (acquired by Allergan)Cynosure (a division of Hologic)
Challenger1
Strong scale, closing on the leaders.
Lumenis Ltd.
Contender2
Focused players with pockets of strength.
Cutera Inc.Syneron Candela
Niche2
Specialists in a single segment or region.
BTL IndustriesVenus Concept
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Area in North America, then scale across CoolSculpting or Zeltiq Market — a $443M beachhead inside a $7.96B market.
Beachhead (SOM)$443Mobtainable near-term
Serviceable (SAM)$2.87Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Abdomen
Best fit — highest urgency & budget in Treatment Area.
Economic buyer78 fit
Flanks (Love Handles)
Strong fit — clear ROI and a fast path to value.
End user68 fit
Thighs
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Area in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel26%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Area leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win CoolSculpting or Zeltiq Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified21%
Evaluation12%
Closed-won7%
$13.7KCAC
$64KLTV
4.7:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
CoolSculpting or Zeltiq Market is a resilient opportunity — $6.68B by 2033, compounding at 3.3%.
TAM · 2025$5.14Btoday
TAM · 2033$6.68Bforecast
CAGR3.3%2027–2033
Cumulative$52.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.68BTotal addressable market
SAM$2.58BServiceable available market
SOM$511MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.3% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Area.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Area moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.68BLarge & growingTAM by 2033 at 3.3% CAGR
$2.58BServiceable nowreachable with today’s model
$511MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.21BBear2.2% CAGR
$6.68BBase3.3% CAGR
$8.55BBull4.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
CoolSculpting or Zeltiq Market — a $5.59B market by 2033. Plan: grow share from 9.1% to 14.3%.
Market size · 2033$5.59Btotal addressable
Market CAGR4.4%2027–2033
Target share14.3%from 9.1% today
Revenue ambition$800Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 14.3% | Ahead |
| Revenue | $533M | $800M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 33.4% | 44.5% | Ahead |
| Customer retention | 90.5% | 93.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Area
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Area share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $99M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Treatment Area leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the CoolSculpting or Zeltiq Market conversation — a $3.26B market you can size, segment and defend in minutes.
Market size · 2033$3.26Btotal opportunity
Growth4.8%CAGR to 2033
Addressable buyers1,752+accounts in scope
Typical ROI6.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Area
Goal Grow share in Treatment Area
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.6×return on cost, year one
< 3 mopayback period
$46K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Allergan (AbbVie)Zeltiq Aesthetics (acquired by Allergan)Cynosure (a division of Hologic)Cutera Inc.Lumenis Ltd.Syneron CandelaBTL IndustriesVenus Concept+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your CoolSculpting or Zeltiq Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
CoolSculpting or Zeltiq Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Coop Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportCooperative Vehicle Systems Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportCoordinate Boring Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportCoordinate Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportCOP Prefillable Syringes Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportCo-packing Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportCo-Packing Service Market
Market size, share, segmentation and regional forecast.
$923M market · 2025 base year
View reportCopaiba Balsam oil Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportCopaiba Oil Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportCo-parenting App Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportCOPD & Asthma Devices Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportCopd Drug Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.